From: The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer’s disease
NC | MCI | AD | ||
---|---|---|---|---|
N | 71 | 110 | 56 | P-value |
Age (Mean ± SE) | 76.5 ± 0.7 | 75.6 ± 0.7 | 74.9 ± 1.0 | 0.19 |
Sex (M/F) | 36/35 | 72/38 | 30/26 | 0.11 |
CDR-SB (Mean ± SE) | 0.04 ± 0.02 | 1.55 ± 0.09 | 4.13 ± 0.20 | <0.001 |
APOE ε4 Dose (0/1/2) | 56/14/1 | 47/49/14 | 17/25/14 | <0.001 |
CSF amyloid β1-42 (Mean ± SE) | 209.2 ± 6.2 | 158.6 ± 4.7 | 139.3 ± 4.4 | <0.001 |
CSF ptau181p (Mean ± SE) | 25.5 ± 1.7 | 36.2 ± 1.5 | 43.0 ± 2.6 | <0.001 |
CSF C3 (Mean ± SE) | −2.56 ± 0.02 | −2.57 ± 0.02 | −2.58 ± 0.02 | 0.53 |